Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

Galapagos NV (NASDAQ:GLPG – Get Free Report) has received an average recommendation of “Reduce” from the eight research firms ...

Belgium-based biotech company Galapagos NV's (GLPG) U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a spin-off into two ...

Fintel reports that on January 23, 2025, Barclays downgraded their outlook for Galapagos NV - Depositary Receipt () (NasdaqGS:GLPG) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 48 ...

Belgian biotech company Galapagos NV plans to spin off part of its operations, creating a new listed firm with approximately €2.45 billion ($2.5 billion) in cash. The newly formed company ...

Galapagos NV has a twelve month low of $23.45 and a twelve month high of $40.34. The business’s 50-day moving average price is $26.55 and its two-hundred day moving average price is $27.41 ...

MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) (“Galapagos” or the ...

Will further expand Galapagos’ manufacturing network in the U.S. for improved patient experience.

Barclays downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of EUR 22, down from EUR 30. With Galapagos’ ongoing ...

Galapagos NV (NASDAQ:GLPG) is under modest pressure premarket, down 6% on increased volume on the heels of promising results from Vertex Pharmaceuticals' (NASDAQ:VRTX) triple... BySeeking Alpha ...

A diver's journey to the Galapagos Islands aboard a small expedition ship. Diving with sharks, turtles, sea lions, rays and ...